Summary
Overview
Work History
Education
Skills
Websites
Accomplishments
Affiliations
Timeline
Generic

Kathy Nelson, MBA

Dallas,TX

Summary

My experience involves 20 years of commercial and medical experience in the pharmaceutical/biotech arena. The past nine years have incorporated launching novel therapeutics, device implants, and bi-specific antibodies, as well as cell therapy. My area of focus is the commercialization of transformative therapies for rare diseases with unmet needs. My expertise includes leadership, KOL identification and development, hospital and institution navigation of decision-making, and marketing and data analytics work streams.

Overview

13
13
years of professional experience

Work History

Regional Market - Cellular Therapy Account Director (West)

Pierre Fabre Pharmaceuticals
06.2025 - Current
  • Develop and execute regional business plans which include onboarding authorized treatment centers for an investigational cell therapy (allogenic Virus-specific T cell), account specific pre-approval disease awareness education, and medical expert engagement strategies and tactics.
  • Identify and engage with medical experts and key stakeholders in the fields of bone marrow transplant (BMT), lymphoma, and solid organ transplantation (SOT) specialists managing Post Transplant Lymphoproliferative Disease (PTLD).
  • Design strategy to align processes with transplant centers and engage in site onboarding for allogenic cell therapies.
  • Key contributor to numerous cross-functional workstreams: Brand Planning, Site Readiness / Onboarding, Marketing, Training and Data Analytics.
  • Identify and address potential access barriers to ensure investigational launch product is well positioned for P&T reviews, High Drug Cost Committees, and Academic Hospital / Health System assessments.
  • Facilitate and ensure collective cross-functional communication and relationships with internal teams including Value & Access, Medical Affairs, Legal, Quality, Technical Operations, Marketing and Patient Affairs.

Cellular Therapy Account Director (South Central)

Pierre Fabre Pharmaceuticals
08.2024 - 06.2025
  • Develop a territory in the South-Central Region for an Oncology 'start-up' business unit in Cellular Therapy. Territory includes Hospital and Academic Institutions, Bone Marrow Transplant Centers, Solid Organ Transplantation, and Cellular & Gene Therapy Labs.
  • Develop and execute territory business plans which include account specific strategies and tactics for physician advocacy and timely patient access.
  • Facilitate cross-functional relationships with internal and institutional stakeholders including C-suite, procurement, revenue cycle, P&T Committee.
  • Navigate activities associated with onboarding institutions for cellular therapy (Confidentiality Agreements, Data Processing Agreements, IT Risk Assessments, Trade Agreements, Portal Education & Training, Cellular Therapy product handling).
  • Drive appropriate advocacy of Pierre Fabre products through scientific exchange.
  • Partner with the US Market Access Team to support execution of US access strategy and tactics to ensure patient access.

Hematology / Oncology Specialist (North Texas)

Karyopharm Therapeutics
04.2023 - 04.2024
  • Implement and execute a growth strategy for earlier adoption of selinexor (XPOVIO) for patients with relapsed multiple myeloma; achieved 135% growth Q1/2024.
  • Establish awareness of selinexor (XPOVIO) for patients with relapsed/refractory DLBCL after at least 2 lines of systemic therapy.
  • Manage HCP accounts to uncover patient needs and ensure optimal patient access, effective pull-through, understanding and addressing reimbursement and access challenges.
  • Expertise in Specialty Pharmacy networks, Payer Landscape / Managed Care, Government / Federal payer sectors, Medicare Part D (Pharmacy Benefit design and coverage policy), Billing Codes (Knowledge of medical coding including ICD-10, DRGs, CPTs and HCPCS), Benefit Verification, Prior Authorization, and Patient Services.

Therapeutic Area Manager, Ophthalmology (Retina)

Genentech, Inc
10.2021 - 04.2023
  • Manage Retina Accounts and affiliated Surgical Centers throughout North Texas.
  • Responsible for launch of faricimab (VABYSMO): 1st and only bi-specific antibody for intravitreal use.
  • Responsible for launch of the port delivery system (SUSVIMO) ocular implant for intravitreal use: the 1st and only drug-device combination FDA approved for nAMD (wet, age-related macular degeneration).
  • Develop strategy for implementation of recapturing growth for LUCENTIS, an anti-VEGF therapy / marketing to prospective accounts / promoting efficacy and safety of the science that supports the brand: resulting in increased adoption (market share exceeded 114%).
  • Selected to Marketing Workstreams: establishing organizational alignment of competitive implications, design tactics to out-maneuver potential challenges, build an unsurmountable position based on competitive intelligence.
  • Ability to provide insights to reimbursement landscape, including billing, coding, EMR, formulary decision process, Buy-and-Bill purchasing process, and patient support services.
  • Expertise in Buy-and-Bill, Payer Landscape / Managed Care, Government / Federal payer sectors, Medicare B.

Senior Hematology / Oncology Specialist (Texas)

Acceleron (acquired by Merck, 2021)
07.2019 - 10.2021
  • Develop a territory in the state of Texas for an oncology start-up company in the hematology and oncology landscape..
  • Launch Acceleron’s first Commercial Sales Field Team and first FDA-approved commercial product, luspatercept (Reblozyl®): an erythroid maturation agent indicated for myelodysplastic syndromes (MDS) and patients with beta thalassemia.
  • Execute strategic business plans for swift growth and adoption, and rapid and successful penetration of top-tier accounts.
  • Awarded for Launch Performance and Territory Growth: Exceeding 2020 goals (FDA approval occurred in April 2020, at the height of the pandemic).

Account Executive / Hematology Business Unit

AbbVie, Oncology
01.2018 - 07.2019
  • Launch several indications for venetoclax (VENCLEXTA®), including 1st-line Chronic Lymphocytic Leukemia (CLL), and Acute Myeloid Leukemia (AML).
  • Sales & Marketing Coordination Council (SMCC) for 2019-2020: strategically developing resources with the Marketing Team for the Commercial Field, utilizing CRM initiatives.
  • AML Strike Force Team, providing field business insights, analytics, and competitive intelligence throughout the launch.
  • Responsible for the communication of pharmacy benefit policies for an oral oncolytic in Buy-and-Bill and Specialty Pharmacy.
  • Insights provided to reimbursement landscape including billing, coding, EMR, formulary and pathway decision process, buy and bill purchasing process, and patient support services.

Key Account Specialist (Texas, New Mexico, Arizona, Los Angeles, East Bay/CA)

Amgen
07.2012 - 01.2018
  • Launch several indications for blinatumomab (BLINCYTO®) for both adult and pediatric patients with acute lymphocytic leukemia (ALL).
  • Strategically planned and implemented inpatient-to-outpatient therapy coordination, with the 28-day continuous infusion requirement for therapy.
  • Developed and led inpatient as well as outpatient nurse and pharmacy training for the triage of patient care.
  • Awards include Chairman’s Circle (2016), MVP Leadership (2016), Team Excellence (2014 and 2016), and Ultimate Race Contest (2013 and 2016).
  • Leadership workstreams include: Shark Tank Team (2016), Council of Sales Advisors (2016-2017), and Amgen Women in Network (2015-2017).

Education

Master of Business Administration -

Southern Methodist University, Cox School of Business
Dallas, TX
06.2024

Bachelor of Science - Dental Hygiene

University of Missouri at Kansas City Dental School
Kansas City, MO

Bachelor of Arts - Journalism/Advertising

University of Oklahoma
Norman, OK

Skills

  • Cell and gene therapy
  • Rare disease expertise
  • Launch strategy and excellence
  • KOL development and collaboration
  • Strategic planning
  • Oncology and hematology
  • Bone marrow transplantation (BMT)
  • Immunology
  • Key account management
  • Market access strategies

Accomplishments

ACADEMIC PROJECTS (SMU / Cox School of Business / MBA Program)

Capstone / Complex Problem Solving, January 2024 ~ April 2024 – Consulting Project

· Collaborated with an assigned team to consult Agility Logistics, Kuwait to demystify Generative AI and provide an integrative approach which would streamline internal AI capabilities and contributes to an Internal Rate of Return

Singapore Global Immersion, October 2023 – Consulting Project

· Collaborated with an assigned team to consult Maritime & Port Authority of Singapore (MPA) to create innovative solutions toward their challenges of ‘expanding’ MPA’s workforce/human capital and to achieve their 2040 ‘net zero’ goals through incentives and renewable energy

War Games/Competitive Intelligence, September 2023 – Battle of Consumer Payments

· Collaborated with an assigned team to develop a company strategy which applied fundamentals of competitive intelligence, scenario planning, and war game competition among peers

Santiago, Chile Global Immersion, February 2023 – Consulting Project: 2nd Place

· Collaborated with an assigned team to consult ALDEAS Infantiles SOS on developing, organizing, and potentially implementing a Code of Conduct for employees including a system of policies, procedures, trainings, and solutions for managing behaviors

Affiliations

ADDITIONAL INFORMATION

· 2024 SMU Cox MBA Disney Institute Program: Selected to attend The Disney Institute’s “Leading and Sustaining a Successful Service Culture” through the SMU Business Leadership Center (BLC)

· SMU Business Leadership Center (BLC): Cox ‘Legacy’ Award, Cox ‘Deans Circle ‘Award, Cox ‘Distinguished Business Leader’ Award, and Cox ‘Forum’ Business Leader Award through continuing servant leadership, maintaining leadership roles, and attendance of over 40 leadership seminars while maintaining a GPA above 3.0

· SMU Cox OMBA Ambassador for incoming MBA candidates

· SMU Cox BLC Student Advisory Committee

· Volunteer

Timeline

Regional Market - Cellular Therapy Account Director (West)

Pierre Fabre Pharmaceuticals
06.2025 - Current

Cellular Therapy Account Director (South Central)

Pierre Fabre Pharmaceuticals
08.2024 - 06.2025

Hematology / Oncology Specialist (North Texas)

Karyopharm Therapeutics
04.2023 - 04.2024

Therapeutic Area Manager, Ophthalmology (Retina)

Genentech, Inc
10.2021 - 04.2023

Senior Hematology / Oncology Specialist (Texas)

Acceleron (acquired by Merck, 2021)
07.2019 - 10.2021

Account Executive / Hematology Business Unit

AbbVie, Oncology
01.2018 - 07.2019

Key Account Specialist (Texas, New Mexico, Arizona, Los Angeles, East Bay/CA)

Amgen
07.2012 - 01.2018

Master of Business Administration -

Southern Methodist University, Cox School of Business

Bachelor of Science - Dental Hygiene

University of Missouri at Kansas City Dental School

Bachelor of Arts - Journalism/Advertising

University of Oklahoma

Similar Profiles

CREATE PROFILE